1666-1667 / 1674
University Hospital Erlangen
Ongoing and future projects
(1)
RTOG/NCI Phase II trial protocol
:
•
Re-irradiation with EBRT
•
Eligible pts.: Unicentric LR ≤ 3 cm, no skin involvement, clear margins, 0-3 + LNs
•
Accrual goal: 61 pts.
•
Primary end-point: ≥ G3 side effects occuring within 1 year
(2)
GEC-ESTRO Breast Cancer WG
:
•
Re-irradiation with multi-catheter HDR/PDR BT
•
Multicentric retrospective match-paired analysis is pending
•
Prospective Phase II trial